The recent Ebola outbreak in Africa coincides with a massive Meningitis Vaccine campaign targeting over 100 million Africans; notably including all four African countries (Guinea, Nigeria, Liberia, Sierra Leone) caught in the epicentre of the viral spread.
The cost-effective vaccine, MenAfriVac®,(less than US $0.50 per dose) was “kept outside the cold chain for up to four days at up to 40°C”.
Vaccine Resistance Movement is investigating the link between this extremely toxic experimental vaccine and the sudden surge in cases of Ebola.
No comments:
Post a Comment